United Therapeutics (UTHR) CEO Buys 13K Shares
Tweet
Share
E-mailGet Alerts UTHR Hot Sheet
Join SI Premium – FREE
United Therapeutics Corporation (Nasdaq: UTHR) CEO Martine Rothblatt disclosed the purchase of 12,943 shares on 12/01-12/02 at prices form $41.30-$42, bringing her indirect stake to 580,006 shares which are owned by Trusts.
The shares were purchased pursuant to pre-arranged 10b5-1 trading plans entered into by trusts beneficially owned by the reporting person and the reporting person's spouse.
The shares were purchased pursuant to pre-arranged 10b5-1 trading plans entered into by trusts beneficially owned by the reporting person and the reporting person's spouse.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- United Therapeutics completes enrollment in PPF lung fibrosis trial
- United Therapeutics Corporation Announces Full Enrollment of the TETON-PPF Study of Inhaled Treprostinil for the Treatment of Progressive Pulmonary Fibrosis
- On Holding AG (ONON) Insider Trades
Create E-mail Alert Related Categories
Insider TradesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
